An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)

Grant

Total Award Amount

  • 27344.00
  • Direct Costs

  • 18601.00
  • Sponsor Award Id

  • Contributor

  • Marissa Dean   Investigator  
  • Victor Sung   Principal Investigator